Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider John Paolini Sells 18,413 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 18,413 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $93.39, for a total value of $1,719,590.07. Following the completion of the sale, the insider directly owned 69,922 shares in the company, valued at approximately $6,530,015.58. This represents a 20.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded up $2.49 during trading on Tuesday, hitting $93.29. The stock had a trading volume of 1,021,631 shares, compared to its average volume of 705,858. Kiniksa Pharmaceuticals International, plc has a 12 month low of $37.02 and a 12 month high of $98.48. The company’s 50-day moving average price is $79.39 and its two-hundred day moving average price is $60.29. The company has a market capitalization of $7.28 billion, a PE ratio of 71.76 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The business had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Canaccord Genuity Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price target on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. The Goldman Sachs Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Finally, Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.57.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Allworth Financial LP grew its position in Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after buying an additional 134 shares in the last quarter. Curry Webb Wealth Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at about $29,000. KBC Group NV purchased a new position in Kiniksa Pharmaceuticals International in the 1st quarter worth approximately $34,000. Nykredit A S bought a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $34,000. Finally, USA Financial Formulas purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth about $69,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.